- The University of West Virgina’s Healthy Minds Chestnut Ridge is being submitted to the NIDA CCTN for approval as a site for CTN-0152 Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the treatment of opioid use disorder: A pragmatic, multi-site, double-blind, randomized, placebo-controlled trial (TAB).
- Dr. Judith Feinberg, MD is Co-I and part of the protocol team for CTN-0155 Low-threshold Buprenorphine Treatment at Syringe Services Programs: a Type I Hybrid Effectiveness-implementation Trial. Study launch is targeted for end of March of 2025.
- Dr. Jane Liebschutz, MD, co-PI from CTN-0139, will be a member of the Panel at the CTN Primary Care SIG: Engaging Rural Communities and Practices in Substance Use Research, January 27, 2025. The panel will discuss how CARE for Health synergistically can enhance and contribute to CTN trials.